C4X Discovery Holdings
plc
("C4XD", "C4X
Discovery" or the "Company")
Last day of dealings and update on
Cancellation
25 April
2024 - C4X Discovery Holdings plc
(AIM: C4XD), a pioneering Drug Discovery company, today provides a
further update with regards to the proposed cancellation of
admission of the Company's ordinary shares to trading on AIM (the
"Cancellation"), as originally announced on 27 March 2024 and as
approved by shareholders at the general meeting held on 15 April
2024.
Shareholders are reminded that the last day of
trading in the Ordinary Shares on AIM is today, 25 April 2024, and
Cancellation will become effective at 7:00 a.m. on 26 April 2024.
Following Cancellation, the Company will re-register as a private
company under the name C4X Discovery Holdings Limited.
As previously announced, the Company has
engaged Asset Match (www.assetmatch.com), a firm Authorised and
Regulated by the Financial Conduct Authority (FRN 579310), to
operate an electronic off-market dealing facility for the ordinary
shares. This facility will allow existing shareholders of the
Company and new investors to trade ordinary shares by matching
buyers and sellers through periodic auctions. Further details can
be found on the Company's website www.c4xdiscovery.com.
The Asset Match facility will be effective from 8 a.m. on 26 April
2024. Investors may wish to register on www.assetmatch.com
and add C4X Discovery to their 'Watchlist' to continue to
receive auction/price information and updates.
Shareholders will continue to be able to hold
their shares in uncertificated form (i.e. in CREST) and should
check with their existing stockbroker whether they are willing or
able to trade in unquoted shares. Shareholders wishing to trade
shares through Asset Match must do so through a stockbroker. A
comprehensive list of stockbrokers who have signed up to access the
Asset Match platform is available on request.
Following Cancellation, shareholders are
encouraged to sign up to the Company's email news alerts via the
C4XD website to remain up to date with the Company's developments
as we continue to advance our portfolio and target opportunities as
a private company.
Further details regarding the cancellation and
re-registration are set out in the circular sent to shareholders
dated 27 March 2024. A copy of the circular is available on the
Company's website www.c4xdiscovery.com.
Following Cancellation, Panmure Gordon (UK)
Limited will cease to act as nominated adviser and corporate broker
to the Company.
- Ends -
Contacts
C4X Discovery
Holdings
|
|
Mo Noonan, Communications
|
+44 (0)787 6444977
|
|
|
Panmure Gordon
(UK) Limited (NOMAD and Broker)
|
|
Freddy Crossley, Emma Earl (Corporate
Finance)
|
+44 (0)20 7886 2500
|
Rupert Dearden (Corporate Broking)
|
|
|
|
C4X Discovery
Media - Consilium Strategic Communications
|
|
Mary-Jane Elliott, Chris Gardner
|
+44 (0)203 709 5700
|
Notes to
Editors:
About C4X
Discovery
C4X Discovery (C4XD) is a pioneering Drug Discovery
company, combining scientific expertise with cutting-edge
technologies to efficiently deliver world‑leading medicines. We
have a highly valuable and differentiated approach to Drug
Discovery through our enhanced molecular design and patient
stratification capabilities, generating small molecule drug
candidates across multiple disease indications focused on
immuno-inflammation. We are advancing our internal portfolio which
ranges from early-stage target opportunities to late-stage Drug
Discovery programmes and we have two commercially partnered
programmes with Sanofi and AstraZeneca, and one clinical stage
candidate which has been acquired by Indivior.
For more information visit us at www.c4xdiscovery.com or follow us
on twitter @C4XDiscovery.
About Asset
Match
Asset Match operates an open auction system
where volumes of bids and offers at different prices are displayed
on-screen together with the closing date of the auction. At the end
of each auction period, Asset Match passes this information through
a non-discretionary algorithm that determines a "market-derived"
single clearing price ("Share Price") based on supply and demand
and allocates transactions accordingly. Bids and offers may be
made, amended and withdrawn at any time before the closing date of
each auction.
For more information, see www.assetmatch.com